• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

After GSK and Novartis handoffs, Laekna's drug fails ovarian cancer trial

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 29, 2024 at 10:42: PM
via Shanghai-based biotech Laekna's oral cancer drug afuresertib has failed to significantly improve progression-free survival for ovarian cancer patients in a phase 2 trial.

article source
 

<



Similar threads

cafead
Novartis, GSK and Sanofi Scale Back on Operations and Labor Forces Overseas - Updated
Replies
0
Views
216
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis&#039; Sandoz doubles down on antibiotics with $500M deal for GSK brands
Replies
0
Views
125
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
GSK, Novartis, J&amp;J and Pfizer lead pharma at making their meds accessible: report
Replies
0
Views
157
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis, GSK team up for $3.6m genetic diversity research in Africa
Replies
0
Views
124
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis&#039; asthma triplet beats GSK&#039;s Advair in phase 2 trial
Replies
0
Views
143
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote